Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
MGNX's Cash to Debt is ranked higher than
72% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. MGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MGNX' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Equity to Asset 0.88
MGNX's Equity to Asset is ranked higher than
79% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MGNX: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
MGNX' s Equity to Asset Range Over the Past 10 Years
Min: -0.26  Med: 0.70 Max: 0.88
Current: 0.88
-0.26
0.88
Interest Coverage No Debt
MGNX's Interest Coverage is ranked lower than
56% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: 9.76
M-Score: -2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -10.82
MGNX's Operating margin (%) is ranked higher than
65% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. MGNX: -10.82 )
Ranked among companies with meaningful Operating margin (%) only.
MGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -80.16  Med: 4.91 Max: 12.86
Current: -10.82
-80.16
12.86
Net-margin (%) -10.91
MGNX's Net-margin (%) is ranked higher than
65% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. MGNX: -10.91 )
Ranked among companies with meaningful Net-margin (%) only.
MGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -80.16  Med: 5.65 Max: 13.1
Current: -10.91
-80.16
13.1
ROE (%) -5.14
MGNX's ROE (%) is ranked higher than
71% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. MGNX: -5.14 )
Ranked among companies with meaningful ROE (%) only.
MGNX' s ROE (%) Range Over the Past 10 Years
Min: -38.27  Med: -19.51 Max: -0.74
Current: -5.14
-38.27
-0.74
ROA (%) -4.17
MGNX's ROA (%) is ranked higher than
72% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. MGNX: -4.17 )
Ranked among companies with meaningful ROA (%) only.
MGNX' s ROA (%) Range Over the Past 10 Years
Min: -25.57  Med: -0.29 Max: 14.36
Current: -4.17
-25.57
14.36
ROC (Joel Greenblatt) (%) -130.80
MGNX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. MGNX: -130.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -648.31  Med: 8.82 Max: 502.14
Current: -130.8
-648.31
502.14
» MGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

MGNX Guru Trades in Q4 2014

Stanley Druckenmiller 472,500 sh (New)
Julian Robertson 185,775 sh (New)
Paul Tudor Jones 9,954 sh (New)
First Eagle Investment 339,285 sh (+1.50%)
Steven Cohen 1,538,771 sh (+1.16%)
George Soros 19,488 sh (unchged)
John Griffin 1,350,000 sh (unchged)
Ronald Muhlenkamp 16,725 sh (-1.47%)
» More
Q1 2015

MGNX Guru Trades in Q1 2015

Ronald Muhlenkamp 66,405 sh (+297.04%)
Steven Cohen 2,350,951 sh (+52.78%)
Paul Tudor Jones 14,089 sh (+41.54%)
First Eagle Investment 393,181 sh (+15.89%)
George Soros 19,488 sh (unchged)
Julian Robertson 185,775 sh (unchged)
John Griffin 1,350,000 sh (unchged)
Stanley Druckenmiller 472,500 sh (unchged)
» More
Q2 2015

MGNX Guru Trades in Q2 2015

Joel Greenblatt 32,087 sh (New)
Julian Robertson 333,275 sh (+79.40%)
Steven Cohen 2,547,084 sh (+8.34%)
Ronald Muhlenkamp 66,500 sh (+0.14%)
George Soros 19,488 sh (unchged)
First Eagle Investment 393,181 sh (unchged)
John Griffin 1,350,000 sh (unchged)
Stanley Druckenmiller Sold Out
Paul Tudor Jones Sold Out
» More
Q3 2015

MGNX Guru Trades in Q3 2015

Jim Simons 26,224 sh (New)
Julian Robertson 403,275 sh (+21.00%)
First Eagle Investment 403,181 sh (+2.54%)
Ronald Muhlenkamp 66,500 sh (unchged)
George Soros 19,488 sh (unchged)
John Griffin 1,350,000 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 2,530,700 sh (-0.64%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.67
MGNX's P/B is ranked higher than
71% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. MGNX: 1.67 )
Ranked among companies with meaningful P/B only.
MGNX' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 4.28 Max: 12.85
Current: 1.67
1.65
12.85
P/S 5.22
MGNX's P/S is ranked higher than
67% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. MGNX: 5.22 )
Ranked among companies with meaningful P/S only.
MGNX' s P/S Range Over the Past 10 Years
Min: 1.12  Med: 7.61 Max: 20.49
Current: 5.22
1.12
20.49
Current Ratio 16.55
MGNX's Current Ratio is ranked higher than
87% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. MGNX: 16.55 )
Ranked among companies with meaningful Current Ratio only.
MGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.65 Max: 16.55
Current: 16.55
1.35
16.55
Quick Ratio 16.55
MGNX's Quick Ratio is ranked higher than
88% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. MGNX: 16.55 )
Ranked among companies with meaningful Quick Ratio only.
MGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.65 Max: 16.55
Current: 16.55
1.35
16.55
Days Sales Outstanding 10.20
MGNX's Days Sales Outstanding is ranked higher than
89% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. MGNX: 10.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
MGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.7  Med: 17.14 Max: 22.41
Current: 10.2
11.7
22.41

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.73
MGNX's Price/Net Cash is ranked higher than
85% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. MGNX: 1.73 )
Ranked among companies with meaningful Price/Net Cash only.
MGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.29  Med: 5.02 Max: 9.94
Current: 1.73
2.29
9.94
Price/Net Current Asset Value 1.70
MGNX's Price/Net Current Asset Value is ranked higher than
85% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. MGNX: 1.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.25  Med: 4.86 Max: 9.52
Current: 1.7
2.25
9.52
Price/Tangible Book 1.64
MGNX's Price/Tangible Book is ranked higher than
82% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. MGNX: 1.64 )
Ranked among companies with meaningful Price/Tangible Book only.
MGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.16  Med: 4.62 Max: 8.76
Current: 1.64
2.16
8.76
Price/Median PS Value 0.69
MGNX's Price/Median PS Value is ranked higher than
64% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. MGNX: 0.69 )
Ranked among companies with meaningful Price/Median PS Value only.
MGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 0.82 Max: 2.63
Current: 0.69
0.16
2.63
Earnings Yield (Greenblatt) (%) -5.39
MGNX's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. MGNX: -5.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5.39  Med: 0.20 Max: 1.5
Current: -5.39
-5.39
1.5

More Statistics

Revenue(Mil) $98
EPS $ -0.43
Short Percentage of Float9.96%
52-Week Range $15.70 - 39.90
Shares Outstanding(Mil)34.31

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 108 44 40 60
EPS($) -0.18 -2.36 -2.93 -2.75
EPS without NRI($) -0.18 -2.36 -2.93 -2.75

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:M55.Germany,
Macrogenics Inc was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company, engaged in discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company currently has a manufacturing facility located in Rockville, Maryland. The Company has three versatile, proprietary technology platforms consisting of: its Dual Affinity Re-Targeting ("DART") platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient's body to destroy targeted cancer cells; its Fc Optimization platform, which enhances the body's immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity ("ADCC") in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and its Cancer Stem-like Cell ("CSLC") platform, which provides a discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. It currently has two oncology product candidates in clinical development. The product candidates are subject to regulation in the United States by the Food and Drug Administration as biological products.
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
MacroGenics to Present at the LEERINK Partners 5th Annual Global Healthcare Conference Feb 04 2016
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : December 14, 2015 Dec 14 2015
MacroGenics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 10 2015
MACROGENICS INC Financials Dec 08 2015
MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference Dec 02 2015
MacroGenics to Present at the Oppenheimer 26th Annual Healthcare Conference Dec 02 2015
Should You Buy MacroGenics Inc (MGNX)? Dec 02 2015
Is Capital Product Partners L.P. (CPLP) Going to Burn These Hedge Funds? Nov 29 2015
Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC... Nov 07 2015
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results Nov 05 2015
MacroGenics reports 3Q loss Nov 04 2015
MacroGenics reports 3Q loss Nov 04 2015
MacroGenics Inc Earnings Call scheduled for 4:30 pm ET today Nov 04 2015
MACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 04 2015
MacroGenics to Participate in Two Upcoming Investor Conferences Nov 04 2015
MacroGenics Announces Date of Third Quarter 2015 Financial Results Conference Call Oct 28 2015
MACROGENICS INC Files SEC form 8-K, Other Events Oct 28 2015
Maryland pharmaceutical company teams with Merck on cancer immunotherapy trial Oct 26 2015
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination... Oct 22 2015
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination... Oct 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK